1
|
Ge Z, Long L, Zhang F, Dong R, Chen Z, Tang S, Yang L, Wang Y. Development of an injectable oxidized dextran/gelatin hydrogel capable of promoting the healing of alkali burn-associated corneal wounds. Int J Biol Macromol 2024; 273:132740. [PMID: 38825267 DOI: 10.1016/j.ijbiomac.2024.132740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 05/22/2024] [Accepted: 05/27/2024] [Indexed: 06/04/2024]
Abstract
The cornea serves as an essential shield that protects the underlying eye from external conditions, yet it remains highly vulnerable to injuries that could lead to blindness and scarring if not promptly and effectively treated. Excessive inflammatory response constitute the primary cause of pathological corneal injury. This study aimed to develop effective approaches for enabling the functional repair of corneal injuries by combining nanoparticles loaded with anti-inflammatory agents and an injectable oxidized dextran/gelatin/borax hydrogel. The injectability and self-healing properties of developed hydrogels based on borate ester bonds and dynamic Schiff base bonds were excellent, improving the retention of administered drugs on the ocular surface. In vitro cellular assays and in vivo animal studies collectively substantiated the proficiency of probucol nanoparticle-loaded hydrogels to readily suppress proinflammatory marker expression and to induce the upregulation of anti-inflammatory mediators, thereby supporting rapid repair of rat corneal tissue following alkali burn-induced injury. As such, probucol nanoparticle-loaded hydrogels represent a prospective avenue to developing long-acting and efficacious therapies for ophthalmic diseases.
Collapse
Affiliation(s)
- Zhengwei Ge
- Aier Eye Hospital, Jinan University, Guangzhou, Guangdong Province 510071, China; Changsha Aier Eye Hospital, Changsha, Hunan Province 410000, China
| | - Linyu Long
- Aier Academy of Ophthalmology, Central South University, Changsha, Hunan 410009, China; Aier Eye Institute, Aier Eye Hospital Group, Changsha, Hunan Province 410035, China; National Engineering Research Center for Biomaterials, Chuanda-Jinbo Joint Research Center, Sichuan University, Chengdu, 610064, China; Eye Center of Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Fanjun Zhang
- National Engineering Research Center for Biomaterials, Chuanda-Jinbo Joint Research Center, Sichuan University, Chengdu, 610064, China
| | - Ruiqi Dong
- National Engineering Research Center for Biomaterials, Chuanda-Jinbo Joint Research Center, Sichuan University, Chengdu, 610064, China
| | - Zhongping Chen
- Aier Eye Hospital, Jinan University, Guangzhou, Guangdong Province 510071, China; Changsha Aier Eye Hospital, Changsha, Hunan Province 410000, China; Aier Academy of Ophthalmology, Central South University, Changsha, Hunan 410009, China; School of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei Province, China.
| | - Shibo Tang
- Changsha Aier Eye Hospital, Changsha, Hunan Province 410000, China; Aier Academy of Ophthalmology, Central South University, Changsha, Hunan 410009, China; Aier Eye Institute, Aier Eye Hospital Group, Changsha, Hunan Province 410035, China.
| | - Li Yang
- National Engineering Research Center for Biomaterials, Chuanda-Jinbo Joint Research Center, Sichuan University, Chengdu, 610064, China
| | - Yunbing Wang
- National Engineering Research Center for Biomaterials, Chuanda-Jinbo Joint Research Center, Sichuan University, Chengdu, 610064, China
| |
Collapse
|
2
|
He Y, Jiang S, Cui Y, Liang J, Zhong Y, Sun Y, Moran MF, Huang Z, He G, Mao X. Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis. Cancer Lett 2024; 588:216797. [PMID: 38462032 DOI: 10.1016/j.canlet.2024.216797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 01/27/2024] [Accepted: 03/05/2024] [Indexed: 03/12/2024]
Abstract
Induction of pyroptosis is proposed as a promising strategy for the treatment of hematological malignancies, but little is known. In the present study, we find clioquinol (CLQ), an anti-parasitic drug, induces striking myeloma and leukemia cell pyroptosis on a drug screen. RNA sequencing reveals that the interferon-inducible genes IFIT1 and IFIT3 are markedly upregulated and are essential for CLQ-induced GSDME activation and cell pyroptosis. Specifically, IFIT1 and IFIT3 form a complex with BAX and N-GSDME therefore directing N-GSDME translocalization to mitochondria and increasing mitochondrial membrane permeabilization and triggering pyroptosis. Furthermore, venetoclax, an activator of BAX and an inhibitor of Bcl-2, displays strikingly synergistic effects with CLQ against leukemia and myeloma via pyroptosis. This study thus reveals a novel mechanism for mitochondrial GSDME in pyroptosis and it also illustrates that induction of IFIT1/T3 and inhibition of Bcl-2 orchestrate the treatment of leukemia and myeloma via pyroptosis.
Collapse
Affiliation(s)
- Yuanming He
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China
| | - Shuoyi Jiang
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China
| | - Yaoli Cui
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China
| | - Jingpei Liang
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China
| | - Yueya Zhong
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China
| | - Yuening Sun
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China
| | - Michael F Moran
- The Department of Molecular Genetics, The University of Toronto, Toronto, ON, M5G 0A4, Canada; Program in Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada
| | - Zhenqian Huang
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China
| | - Guisong He
- Department of Orthopedics, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China
| | - Xinliang Mao
- The Key Laboratory of Advanced Interdisciplinary Studies, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China.
| |
Collapse
|
3
|
Fan K, Dong N, Fang M, Xiang Z, Zheng L, Wang M, Shi Y, Tan G, Li C, Xue Y. Ozone exposure affects corneal epithelial fate by promoting mtDNA leakage and cGAS/STING activation. JOURNAL OF HAZARDOUS MATERIALS 2024; 465:133219. [PMID: 38101018 DOI: 10.1016/j.jhazmat.2023.133219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 11/29/2023] [Accepted: 12/08/2023] [Indexed: 12/17/2023]
Abstract
Ozone is a common air pollutant associated with various human diseases. The human ocular surface is frequently exposed to ozone in the troposphere, but the mechanisms by which ozone affects the ocular surface health remain unclear. This study aimed to establish a mouse model to investigate the effects of ozone exposure on the ocular surface and the corneal epithelium. The findings revealed that ozone exposure disrupted corneal epithelial homeostasis and differentiation, resulting in corneal squamous metaplasia. Further, ozone exposure induced oxidative damage and cytoplasmic leakage of mitochondrial DNA (mtDNA), thereby activating the cGAS/STING signaling pathway. The activation of the cGAS/STING signaling pathway triggered the activation of downstream NF-κB and TRAF6 signaling pathways, causing corneal inflammation, thereby promoting corneal inflammation and squamous metaplasia. Finally, C-176, a selective STING inhibitor, effectively prevented and treated corneal inflammation and squamous metaplasia caused by ozone exposure. This study revealed the role of mtDNA leakage-mediated cGAS/STING activation in corneal squamous epithelial metaplasia caused by ozone exposure. It also depicted the abnormal expression pattern of corneal epithelial keratin using three-dimensional images, providing new targets and strategies for preventing and treating corneal squamous metaplasia and other ocular surface diseases.
Collapse
Affiliation(s)
- Kai Fan
- Eye Institute & Affiliated Xiamen Eye Center, School of Pharmaceutical Sciences & School of Medicine, Xiamen University, Xiamen, Fujian 361102, China; School of Pharmaceutical Sciences, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian 361102, China
| | - Nuo Dong
- Eye Institute & Affiliated Xiamen Eye Center, School of Pharmaceutical Sciences & School of Medicine, Xiamen University, Xiamen, Fujian 361102, China; Huaxia Eye Hospital of Quanzhou, Quanzhou, Fujian 362000, China
| | - Meichai Fang
- Ningde People's Hospital, Ningde, Fujian 352100, China
| | - Zixun Xiang
- School of Pharmaceutical Sciences, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian 361102, China
| | - Lan Zheng
- Eye Institute & Affiliated Xiamen Eye Center, School of Pharmaceutical Sciences & School of Medicine, Xiamen University, Xiamen, Fujian 361102, China
| | - Mengyuan Wang
- Eye Institute & Affiliated Xiamen Eye Center, School of Pharmaceutical Sciences & School of Medicine, Xiamen University, Xiamen, Fujian 361102, China
| | - Yukuan Shi
- The High School Affiliated to Renmin University of China, 100080, China
| | - Gang Tan
- The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.
| | - Cheng Li
- Eye Institute & Affiliated Xiamen Eye Center, School of Pharmaceutical Sciences & School of Medicine, Xiamen University, Xiamen, Fujian 361102, China; Huaxia Eye Hospital of Quanzhou, Quanzhou, Fujian 362000, China; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science & Ocular Surface and Corneal Diseases, Xiamen, Fujian 361102, China; The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.
| | - Yuhua Xue
- Eye Institute & Affiliated Xiamen Eye Center, School of Pharmaceutical Sciences & School of Medicine, Xiamen University, Xiamen, Fujian 361102, China; School of Pharmaceutical Sciences, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian 361102, China.
| |
Collapse
|
4
|
Wang W, Li J, Cui S, Li J, Ye X, Wang Z, Zhang T, Jiang X, Kong Y, Chen X, Chen YQ, Zhu S. Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome. SCIENCE ADVANCES 2024; 10:eadj7813. [PMID: 38306420 PMCID: PMC10836723 DOI: 10.1126/sciadv.adj7813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Accepted: 01/03/2024] [Indexed: 02/04/2024]
Abstract
Metabolic syndrome (MetS) is closely associated with an increased risk of dementia and cognitive impairment, and a complex interaction of genetic and environmental dietary factors may be implicated. Free fatty acid receptor 4 (Ffar4) may bridge the genetic and dietary aspects of MetS development. However, the role of Ffar4 in MetS-related cognitive dysfunction is unclear. In this study, we found that Ffar4 expression is down-regulated in MetS mice and MetS patients with cognitive impairment. Conventional and microglial conditional knockout of Ffar4 exacerbated high-fat diet (HFD)-induced cognitive dysfunction and anxiety, whereas microglial Ffar4 overexpression improved HFD-induced cognitive dysfunction and anxiety. Mechanistically, we found that microglial Ffar4 regulated microglial activation through type I interferon signaling. Microglial depletion and NF-κB inhibition partially reversed cognitive dysfunction and anxiety in microglia-specific Ffar4 knockout MetS mice. Together, these findings uncover a previously unappreciated role of Ffar4 in negatively regulating the NF-κB-IFN-β signaling and provide an attractive therapeutic target for delaying MetS-associated cognitive decline.
Collapse
Affiliation(s)
- Wei Wang
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
| | - Jinyou Li
- Affiliated Hospital of Jiangnan University, Wuxi 214122, China
| | - Siyuan Cui
- Jiangnan University Medical Center, Wuxi 214002, China
| | - Jiayu Li
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
| | - Xianlong Ye
- Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China
| | - Zhe Wang
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
| | - Tingting Zhang
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
| | - Xuan Jiang
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
| | - Yulin Kong
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
| | - Xin Chen
- Jiangnan University Medical Center, Wuxi 214002, China
| | - Yong Q. Chen
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
| | - Shenglong Zhu
- Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China
- Jiangnan University Medical Center, Wuxi 214002, China
| |
Collapse
|